The unpaved journey of vitamin c in cancer treatment

Canadian Journal of Physiology and Pharmacology

Volumn 93, Issue 12, 2015, Pages 1055-1063

  Chen, Qi ^a   Polireddy, Kishore ^a   Chen, Ping ^a   Dong, Ruochen ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Ascorbate; Ascorbic acid; Cancer; Vitamin C

Indexed keywords

ASCORBIC ACID;

ALTERNATIVE MEDICINE; CANCER THERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; ANIMAL; NEOPLASMS;

ANIMALS; ASCORBIC ACID; HUMANS; NEOPLASMS;

EID: 84947563635     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2014-0509     Document Type: Review

References (92)

1. 2 mediate glucose deprivation-induced stress in human cancer cells. J. Biol. Chem. 280(6): 4254–4263. doi:10.1074/jbc.M411662200. PMID:15561720.
2. Buettner, G.R. 1986. Ascorbate autoxidation in the presence of iron and copper chelates. Free Radic. Res. Commun. 1(6): 349–353. doi:10.3109/10715768609051638. PMID:2851502.
3. Burns, J.J., Moltz, A., and Peyser, P. 1956. Missing step in guinea pigs required for the biosynthesis of L-ascorbic acid. Science, 124(3232): 1148–1149. doi:10.1126/science.124.3232.1148-a. PMID:13380431.
4. Cameron, E., and Campbell, A. 1974. The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem. Biol. Interact. 9(4): 285–315. doi:10.1016/0009-2797(74)90019-2. PMID:4430016.
5. Cameron, E., and Campbell, A. 1991. Innovation vs. quality control: an ‘unpublishable’ clinical trial of supplemental ascorbate in incurable cancer. Med. Hypotheses, 36(3): 185–189. doi:10.1016/0306-9877(91)90127-K. PMID:1787807.
6. Cameron, E., and Pauling, L. 1976. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc. Natl. Acad. Sci. U.S.A. 73(10): 3685–3689. doi:10.1073/pnas.73.10.3685. PMID:1068480.
7. Cameron, E., and Pauling, L. 1978. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc. Natl. Acad. Sci. U.S.A. 75(9): 4538–4542. doi:10.1073/pnas.75.9.4538. PMID:279931.
8. Cameron, E., and Pauling, L. 1993. Cancer and Vitamin C. Camino Books, Inc., Philadelphia, Pa.
9. Cameron, E., Campbell, A., and Jack, T. 1975. The orthomolecular treatment of cancer. III. Reticulum cell sarcoma: double complete regression induced by high-dose ascorbic acid therapy. Chem. Biol. Interact. 11(5): 387–393. doi:10.1016/0009-2797(75)90007-1. PMID:1104207.
10. Carosio, R., Zuccari, G., Orienti, I., Mangraviti, S., and Montaldo, P.G. 2007. Sodium ascorbate induces apoptosis in neuroblastoma cell lines by interfering with iron uptake. Mol. Cancer, 6: 55. doi:10.1186/1476-4598-6-55. PMID: 17760959.
11. Chen, P., Yu, J., Chalmers, B., Drisko, J., Yang, J., Li, B., and Chen, Q. 2011. Pharmacological ascorbate induces cytotoxicity in prostate cancer cells through ATP depletion and induction of autophagy. Anticancer Drugs, 23(4): 437–444. doi:10.1097/CAD.0b013e32834fd01f. PMID:22205155.
12. Chen, Q., Espey, M.G., Krishna, M.C., Mitchell, J.B., Corpe, C.P., Buettner, G.R., et al. 2005. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc. Natl. Acad. Sci. U.S.A. 102(38): 13604–13609. doi:10.1073/pnas.0506390102. PMID: 16157892.
13. Chen, Q., Espey, M.G., Sun, A.Y., Lee, J.H., Krishna, M.C., Shacter, E., et al. 2007. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc. Natl. Acad. Sci. U.S.A. 104(21): 8749–8754. doi:10.1073/pnas.0702854104. PMID:17502596.
14. Chen, Q., Espey, M.G., Sun, A.Y., Pooput, C., Kirk, K.L., Krishna, M.C., et al. 2008. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc. Natl. Acad. Sci. U.S.A. 105(32): 11105–11109. doi:10.1073/pnas.0804226105. PMID:18678913.
15. Clement, M.V., Ramalingam, J., Long, L.H., and Halliwell, B. 2001. The in vitro cytotoxicity of ascorbate depends on the culture medium used to perform the assay and involves hydrogen peroxide. Antioxid. Redox Signal. 3(1): 157–163. doi:10.1089/152308601750100687. PMID:11291594.
16. Comelli, M., Di Pancrazio, F., and Mavelli, I. 2003. Apoptosis is induced by decline of mitochondrial ATP synthesis in erythroleukemia cells. Free Radic. Biol. Med. 34(9): 1190–1199. doi:10.1016/S0891-5849(03)00107-2. PMID:12706499.
17. Creagan, E.T., Moertel, C.G., O’Fallon, J.R., Schutt, A.J., O’Connell, M.J., Rubin, J., and Frytak, S. 1979. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N. Engl. J. Med. 301(13): 687–690. doi:10.1056/NEJM197909273011303. PMID:384241.
18. Cullen, J.J. 2010. Ascorbate induces autophagy in pancreatic cancer. Autophagy, 6(3): 421–422. doi:10.4161/auto.6.3.11527. PMID:20400857.
19. Deubzer, B., Mayer, F., Kuci, Z., Niewisch, M., Merkel, G., Handgretinger, R., and Bruchelt, G. 2010. H(2)O(2)-mediated cytotoxicity of pharmacologic ascorbate concentrations to neuroblastoma cells: potential role of lactate and ferritin. Cell. Physiol. Biochem. 25(6): 767–774. doi:10.1159/000315098. PMID:20511723.
20. Drisko, J.A., Chapman, J., and Hunter, V.J. 2003. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. J. Am. Coll. Nutr. 22(2): 118–123. doi:10.1080/07315724.2003.10719284. PMID:12672707.
21. Du, J., Martin, S.M., Levine, M., Wagner, B.A., Buettner, G.R., Wang, S.H., et al. 2010. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin. Cancer Res. 16(2): 509–520. doi:10.1158/1078-0432.CCR-09-1713. PMID: 20068072.
22. Espey, M.G., Chen, P., Chalmers, B., Drisko, J., Sun, A.Y., Levine, M., and Chen, Q. 2011. Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic. Biol. Med 50(11): 1610–1619. doi:10.1016/j.freeradbiomed.2011.03.007. PMID:21402145.
23. Evans, M.K., Tovmasyan, A., Batinic-Haberle, I., and Devi, G.R. 2014. Mn porphyrin in combination with ascorbate acts as a pro-oxidant and mediates caspase-independent cancer cell death. Free Radic. Biol. Med. 68: 302–314. doi:10.1016/j.freeradbiomed.2013.11.031. PMID:24334253.
24. Farah, I.O., Lewis, V.L., Ayensu, W.K., and Mahmud, O. 2011. Assessing the survival of mrc-5 and a549 cell lines upon exposure to ascorbic Acid and sodium ascorbate: Biomed 2011. Biomed. Sci. Instrum. 47: 201–206. PMID:21525621.
25. Gilloteaux, J., Jamison, J.M., Arnold, D., Ervin, E., Eckroat, L., Docherty, J.J., et al. 1998. Cancer cell necrosis by autoschizis: synergism of antitumor activity of vitamin C: vitamin K3 on human bladder carcinoma T24 cells. Scanning, 20(8): 564–575. doi:10.1002/sca.4950200805. PMID:9891940.
26. Gilloteaux, J., Jamison, J.M., Arnold, D., Taper, H.S., and Summers, J.L. 2001. Ultrastructural aspects of autoschizis: a new cancer cell death induced by the synergistic action of ascorbate/menadione on human bladder carcinoma cells. Ultrastruct. Pathol. 25(3): 183–192. doi:10.1080/019131201300343810. PMID:11465474.
27. Gilloteaux, J., Jamison, J.M., Neal, D.R., and Summers, J.L. 2005. Cell death by autoschizis in TRAMP prostate carcinoma cells as a result of treatment by ascorbate: menadione combination. Ultrastruct. Pathol. 29(3–4): 221–235. doi:10.1080/01913120590951239. PMID:16036878.
28. Gilloteaux, J., Jamison, J.M., Neal, D.R., Loukas, M., Doberzstyn, T., and Summers, J.L. 2010. Cell damage and death by autoschizis in human bladder (RT4) carcinoma cells resulting from treatment with ascorbate and menadione. Ultrastruct. Pathol. 34(3): 140–160. doi:10.3109/01913121003662304. PMID:20455663.
29. Gilloteaux, J., Jamison, J.M., Neal, D., and Summers, J.L. 2014. Synergistic antitumor cytotoxic actions of ascorbate and menadione on human prostate (DU145) cancer cells in vitro: nucleus and other injuries preceding cell death by autoschizis. Ultrastruct. Pathol. 38(2): 116–140. doi:10.3109/01913123.2013.852645. PMID:24460713.
30. Graumlich, J.F., Ludden, T.M., Conry-Cantilena, C., Cantilena, L.R., Jr., Wang, Y., and Levine, M. 1997. Pharmacokinetic model of ascorbic acid in healthy male volunteers during depletion and repletion. Pharm. Res. 14(9): 1133–1139. doi: 10.1023/A:1012186203165. PMID:9327438.
31. Hayashi, M.T., and Karlseder, J. 2013. DNA damage associated with mitosis and cytokinesis failure. Oncogene, 32(39): 4593–4601. doi:10.1038/onc.2012.615. PMID:23318447.
32. Henson, D.E., Block, G., and Levine, M. 1991. Ascorbic acid: biologic functions and relation to cancer. J. Natl. Cancer Inst. 83(8): 547–550. doi:10.1093/jnci/83.8.547. PMID:1672383.
33. Herst, P.M., Broadley, K.W., Harper, J.L., and McConnell, M.J. 2012. Pharmacological concentrations of ascorbate radiosensitize glioblastoma multiforme primary cells by increasing oxidative DNA damage and inhibiting G2/M arrest. Free Radic. Biol. Med. 52(8): 1486–1493. doi:10.1016/j.freeradbiomed.2012.01.021. PMID:22342518.
34. Hoffer, L.J., Levine, M., Assouline, S., Melnychuk, D., Padayatty, S.J., Rosadiuk, K., et al. 2008. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann. Oncol. 19(11): 1969–1974. doi:10.1093/annonc/mdn377. PMID:18544557.
35. Hong, S.W., Jin, D.H., Hahm, E.S., Yim, S.H., Lim, J.S., Kim, K.I., et al. 2007. Ascorbate (vitamin C) induces cell death through the apoptosis-inducing factor in human breast cancer cells. Oncol. Rep. 18(4): 811–815. doi:10.3892/or.18.4.811. PMID:17786340.
36. Huang, Q., Wu, Y.T., Tan, H.L., Ong, C.N., and Shen, H.M. 2009. A novel function of poly(ADP-ribose) polymerase-1 in modulation of autophagy and necrosis under oxidative stress. Cell Death Differ. 16(2): 264–277. doi:10.1038/cdd.2008.151. PMID:18974775.
37. Hyslop, P.A., Hinshaw, D.B., Halsey, W.A., Jr., Schraufstatter, I.U., Sauerheber, R.D., Spragg, R.G., et al. 1988. Mechanisms of oxidant-mediated cell injury. The glycolytic and mitochondrial pathways of ADP phosphorylation are major intracellular targets inactivated by hydrogen peroxide. J. Biol. Chem. 263(4): 1665–1675. PMID:3338986.
38. Jamison, J.M., Gilloteaux, J., Taper, H.S., and Summers, J.L. 2001. Evaluation of the in vitro and in vivo antitumor activities of vitamin C and K-3 combinations against human prostate cancer. J. Nutr. 131(1): 158S–160S. PMID: 11208954.
39. Kang, J.S., Cho, D., Kim, Y.I., Hahm, E., Yang, Y., Kim, D., et al. 2003. L-ascorbic acid (vitamin C) induces the apoptosis of B16 murine melanoma cells via a caspase-8-independent pathway. Cancer Immunol. Immunother. 52(11): 693–698. doi:10.1007/s00262-003-0407-6. PMID:12827307.
40. Kelley, E.E., Domann, F.E., Buettner, G.R., Oberley, L.W., and Burns, C.P. 1997. Increased efficacy of in vitro photofrin photosensitization of human oral squamous cell carcinoma by iron and ascorbate. J. Photochem. Photobiol. B, 40(3): 273–277. doi:10.1016/S1011-1344(97)00068-7. PMID:9372616.
41. Kuiper, C., Dachs, G.U., Currie, M.J., and Vissers, M.C. 2014. Intracellular ascorbate enhances hypoxia-inducible factor (HIF)-hydroxylase activity and preferentially suppresses the HIF-1 transcriptional response. Free Radic. Biol. Med. doi:10.1016/j.freeradbiomed.2014.01.033. PMID:24495550.
42. Levine, M. 1986. New concepts in the biology and biochemistry of ascorbic acid. N. Engl. J. Med. 314(14): 892–902. doi:10.1056/NEJM198604033141407. PMID: 3513016.
43. Levine, M., Dhariwal, K.R., Washko, P.W., Butler, J.D., Welch, R.W., Wang, Y.H., and Bergsten, P. 1991. Ascorbic acid and in situ kinetics: a new approach to vitamin requirements. Am. J. Clin. Nutr. 54(6 Suppl): 1157S–1162S. PMID: 1962564.
44. Levine, M., Conry-Cantilena, C., Wang, Y., Welch, R.W., Washko, P.W., Dhariwal, K.R., et al. 1996. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc. Natl. Acad. Sci. U.S.A. 93(8): 3704–3709. doi:10.1073/pnas.93.8.3704. PMID:8623000.
45. Levine, M., Rumsey, S., Wang, Y., Park, B., and Daruwala, R. 2000. Vitamin C. In Biochemical and physiological aspects of human nutrition. Edited by M.H. Stipanuk and W.B. Saunders. pp: 541–567.
46. Levine, M., Wang, Y., Padayatty, S.J., and Morrow, J. 2001. A new recommended dietary allowance of vitamin C for healthy young women. Proc. Natl. Acad. Sci. U.S.A. 98(17): 9842–9846. doi:10.1073/pnas.171318198. PMID:11504949.
47. Levine, M., Padayatty, S., and Espey, M. 2011. Vitamin C: a concentration–function approach yields pharmacology and therapeutic discoveries. Adv. Nutr. 2: 78–88. doi:10.3945/an.110.000109. PMID:22332036.
48. Lin, S.Y., Lai, W.W., Chou, C.C., Kuo, H.M., Li, T.M., Chung, J.G., and Yang, J.H. 2006. Sodium ascorbate inhibits growth via the induction of cell cycle arrest and apoptosis in human malignant melanoma A375.S2 cells. Melanoma Res 16(6): 509–519. doi:10.1097/01.cmr.0000232297.99160.9e. PMID:17119452.
49. Ma, Y., Chapman, J., Levine, M., Polireddy, K., Drisko, J., and Chen, Q. 2014. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci. Transl. Med. 6(222): 222ra218. doi:10.1126/scitranslmed.3007154. PMID:24500406.
50. Martini, E. 2002. Jacques Cartier witnesses a treatment for scurvy. Vesalius, 8(1): 2–6. PMID:12422875.
51. Martinotti, S., Ranzato, E., and Burlando, B. 2011. In vitro screening of synergistic ascorbate-drug combinations for the treatment of malignant mesothelioma. Toxicol. In Vitro, 25(8): 1568–1574. doi:10.1016/j.tiv.2011.05.023. PMID:21645609.
52. McCormick, W. 1954. Cancer: the preconditioning factor in pathogenesis; a newetiologic approach. Arch. Pediatr. 71(10): 313–322. PMID:13208373.
53. Mikirova, N., Casciari, J., Rogers, A., and Taylor, P. 2012. Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J. Transl. Med. 10:189. doi:10.1186/1479-5876-10-189. PMID:22963460.
54. Moertel, C.G., Fleming, T.R., Creagan, E.T., Rubin, J., O’Connell, M.J., and Ames, M.M. 1985. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N. Engl. J. Med. 312(3): 137–141. doi:10.1056/NEJM198501173120301. PMID:3880867.
55. Monti, D.A., Mitchell, E., Bazzan, A.J., Littman, S., Zabrecky, G., Yeo, C.J., et al. 2012. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One, 7(1): e29794. doi:10.1371/journal.pone.0029794. PMID:22272248.
56. Murata, A., Morishige, F., and Yamaguchi, H. 1982. Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. Int. J. Vitam. Nutr. Res. Suppl. 23: 103–113. PMID:6811475.
57. Norum, K.R., and Grav, H.J. 2002. Axel Holst and Theodor Frolich–pioneers in the combat of scurvy. [In Norwegian] Tidsskr. Nor. Laegeforen. 122(17): 1686–1687. PMID:12555613.
58. Ohno, S., Ohno, Y., Suzuki, N., Soma, G., and Inoue, M. 2009. High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced cancer. Anticancer Res. 29(3): 809–815. PMID:19414313.
59. Ohtani, S., Iwamaru, A., Deng, W., Ueda, K., Wu, G., Jayachandran, G., et al. 2007. Tumor suppressor 101F6 and ascorbate synergistically and selectively inhibit non-small cell lung cancer growth by caspase-independent apoptosis and autophagy. Cancer Res. 67(13): 6293–6303. doi:10.1158/0008-5472.CAN-06-3884. PMID:17616688.
60. Olney, K.E., Du, J., van’t Erve, T.J., Witmer, J.R., Sibenaller, Z.A., Wagner, B.A., et al. 2013. Inhibitors of hydroperoxide metabolism enhance ascorbateinduced cytotoxicity. Free Radic. Res. 47(3): 154–163. doi:10.3109/10715762.2012.755263. PMID:23205739.
61. Padayatty, S.J., and Levine, M. 2000. Reevaluation of ascorbate in cancer treatment: emerging evidence, open minds and serendipity. J. Am. Coll. Nutr. 19(4): 423–425. doi:10.1080/07315724.2000.10718941. PMID:10963459.
62. Padayatty, S.J., Sun, H., Wang, Y., Riordan, H.D., Hewitt, S.M., Katz, A., et al. 2004. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann. Intern. Med. 140(7): 533–537. doi:10.7326/0003-4819-140-7-200404060-00010. PMID:15068981.
63. Padayatty, S.J., Riordan, H.D., Hewitt, S.M., Katz, A., Hoffer, L.J., and Levine, M. 2006. Intravenously administered vitamin C as cancer therapy: three cases. CMAJ, 174(7): 937–942. doi:10.1503/cmaj.050346. PMID:16567755.
64. Padayatty, S.J., Sun, A.Y., Chen, Q., Espey, M.G., Drisko, J., and Levine, M. 2010. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One, 5(7): e11414. doi:10.1371/journal.pone.0011414. PMID:20628650.
65. Pelicano, H., Martin, D.S., Xu, R.H., and Huang, P. 2006. Glycolysis inhibition for anticancer treatment. Oncogene, 25(34): 4633–4646. doi:10.1038/sj.onc.1209597. PMID:16892078.
66. Philips, N., Dulaj, L., and Upadhya, T. 2009. Cancer cell growth and extracellular matrix remodeling mechanism of ascorbate; beneficial modulation by P. leucotomos. Anticancer Res. 29(8): 3233–3238. PMID:19661340.
67. Pollard, H.B., Levine, M.A., Eidelman, O., and Pollard, M. 2010. Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormonerefractory prostate cancer. In Vivo, 24(3): 249–255. PMID:20554995.
68. Preddy, V.R., Watson, R.R., and Sherma, Z. 2010. Dietary components and immune function (Nutrition and Health). Humana Press, London, UK. pp. 36.
69. Rawal, M., Schroeder, S.R., Wagner, B.A., Cushing, C.M., Welsh, J.L., Button, A.M., et al. 2013. Manganoporphyrins increase ascorbate-induced cytotoxicity by enhancing H2O2 generation. Cancer Res. 73(16): 5232–5241. doi:10.1158/0008-5472.CAN-13-0470. PMID:23764544.
70. Riordan, H.D., Casciari, J.J., Gonzalez, M.J., Riordan, N.H., Miranda-Massari, J.R., Taylor, P., and Jackson, J.A. 2005. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P. R. Health Sci. J. 24(4): 269–276. PMID:16570523.
71. Sinnberg, T., Noor, S., Venturelli, S., Berger, A., Schuler, P., Garbe, C., and Busch, C. 2014. The ROS-induced cytotoxicity of ascorbate is attenuated by hypoxia and HIF-1alpha in the NCI60 cancer cell lines. J. Cell. Mol. Med. 18(3): 530–541. doi:10.1111/jcmm.12207. PMID:24330097.
72. Stephenson, C.M., Levin, R.D., Spector, T., and Lis, C.G. 2013. Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemother. Pharmacol. 72(1): 139–146. doi:10.1007/s00280-013-2179-9. PMID:23670640.
73. Surova, O., and Zhivotovsky, B. 2013. Various modes of cell death induced by DNA damage. Oncogene, 32(33): 3789–3797. doi:10.1038/onc.2012.556. PMID: 23208502.
74. Takahashi, H., Mizuno, H., and Yanagisawa, A. 2012. High-dose intravenous vitamin C improves quality of life in cancer patients. Personalized Medicine Universe, 1(1): 49–53. doi:10.1016/j.pmu.2012.05.008.
75. Takemura, Y., Satoh, M., Satoh, K., Hamada, H., Sekido, Y., and Kubota, S. 2010. High dose of ascorbic acid induces cell death in mesothelioma cells. Biochem. Biophys. Res. Commun. 394(2): 249–253. doi:10.1016/j.bbrc.2010.02.012. PMID: 20171954.
76. Taper, H.S., Jamison, J.M., Gilloteaux, J., Gwin, C.A., Gordon, T., and Summers, J.L. 2001. In vivo reactivation of DNases in implanted human prostate tumors after administration of a vitamin C/K(3) combination. J. Histochem. Cytochem. 49(1): 109–120. doi:10.1177/002215540104900111. PMID: 11118483.
77. Ullah, M.F., Khan, H.Y., Zubair, H., Shamim, U., and Hadi, S.M. 2010. The antioxidant ascorbic acid mobilizes nuclear copper leading to a prooxidant breakage of cellular DNA: implications for chemotherapeutic action against cancer. Cancer Chemother. Pharmacol. 67(1): 103–110. doi:10.1007/s00280-010-1290-4. PMID:20213077.
78. Verrax, J., and Calderon, P.B. 2009. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic. Biol. Med. 47(1): 32–40. doi:10.1016/j.freeradbiomed.2009.02.016. PMID:19254759.
79. Verrax, J., Cadrobbi, J., Marques, C., Taper, H., Habraken, Y., Piette, J., and Calderon, P.B. 2004. Ascorbate potentiates the cytotoxicity of menadione leading to an oxidative stress that kills cancer cells by a non-apoptotic caspase-3 independent form of cell death. Apoptosis, 9(2): 223–233. doi:10.1023/B:APPT.0000018804.26026.1a. PMID:15004519.
80. Verrax, J., Delvaux, M., Beghein, N., Taper, H., Gallez, B., and Buc Calderon, P. 2005. Enhancement of quinone redox cycling by ascorbate induces a caspase-3 independent cell death in human leukaemia cells. An in vitro comparative study. Free Radic. Res. 39(6): 649–657. doi:10.1080/10715760500097906. PMID: 16036343.
81. Verrax, J., Dejeans, N., Sid, B., Glorieux, C., and Calderon, P.B. 2011. Intracellular ATP levels determine cell death fate of cancer cells exposed to both standard and redox chemotherapeutic agents. Biochem. Pharmacol. 82(11): 1540–1548. doi:10.1016/j.bcp.2011.07.102. PMID:21843513.
82. Vessoni, A.T., Filippi-Chiela, E.C., Menck, C.F., and Lenz, G. 2013. Autophagy and genomic integrity. Cell Death Differ. 20(11): 1444–1454. doi:10.1038/cdd.2013.103. PMID:23933813.
83. Vollbracht, C., Schneider, B., Leendert, V., Weiss, G., Auerbach, L., and Beuth, J. 2011. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo, 25(6): 983–990. PMID:22021693.
84. Warburg, O., Wind, F., and Negelein, E. 1927. The metabolism of tumors in the body. J. Gen. Physiol. 8(6): 519–530. doi:10.1085/jgp.8.6.519. PMID:19872213.
85. Wei, Y., Song, J., Chen, Q., and Xing, D. 2012. Enhancement of photodynamic antitumor effect with pro-oxidant ascorbate. Lasers Surg. Med. 44(1): 69–75. doi:10.1002/lsm.21157. PMID:22246986.
86. Welsh, J.L., Wagner, B.A., van’t Erve, T.J., Zehr, P.S., Berg, D.J., Halfdanarson, T.R., et al. 2013. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother. Pharmacol. 71(3): 765–775. doi:10.1007/s00280-013-2070-8. PMID:23381814.
87. Wendt, J., Radetzki, S., von Haefen, C., Hemmati, P.G., Guner, D., Schulze-Osthoff, K., et al. 2006. Induction of p21CIP/WAF-1 and G2 arrest by ionizing irradiation impedes caspase-3-mediated apoptosis in human carcinoma cells. Oncogene, 25(7): 972–980. doi:10.1038/sj.onc.1209031. PMID:16331277.
88. Wittes, R.E. 1985. Vitamin C and cancer. N. Engl. J. Med. 312(3): 178–179. doi:10.1056/NEJM198501173120310. PMID:3965937.
89. Woodall, J. 1617. The surgions mate, or, A treatise discouering faithfully and plainely the due contents of the surgions chest. Printed by Edward Griffin for Laurence Liesel, at the Tygers-head in Pauls Church-yard London.
90. Xu, R.H., Pelicano, H., Zhou, Y., Carew, J.S., Feng, L., Bhalla, K.N., et al. 2005. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 65(2): 613–621. PMID:15695406.
91. Yeom, C.H., Jung, G.C., and Song, K.J. 2007. Changes of terminal cancer patients’ health-related quality of life after high dose vitamin C administration. J. Korean Med. Sci. 22(1): 7–11. doi:10.3346/jkms.2007.22.1.7. PMID:17297243.
92. Zetterstrom, R. 2009. Nobel Prize 1937 to Albert von Szent-Gyorgyi: identification of vitamin C as the anti-scorbutic factor. Acta Paediatr. 98(5): 915–919. doi:10.1111/j.1651-2227.2009.01239.x. PMID:19239412.